IP Library Patent Application 13422436
Patent Application
App. No. 13/422,436

Ox2 Receptor Homologs

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/422,436
Abstract

Nucleic acids encoding mammalian, e.g., primate, receptors, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.

Claims (12)

1 . A method of treating a patient for rheumatoid arthritis comprising administering to the patient an OX2R-binding antibody or an antigen-binding fragment thereof, comprising an antigen binding site from a substantially pure or recombinant antibody, wherein the antibody specifically binds to an antigen formed by the mature amino acid sequence set forth in SEQ ID NO:20, and wherein the antibody or antigen-binding fragment thereof has agonist activity for the receptor upon binding.

2 . The method of claim 1 , wherein the OX2R-binding antibody is a monoclonal antibody.

3 . The method of claim 2 , wherein the OX2R-binding antibody or the antigen-binding fragment thereof binds the antigen with a K d of at least 30 μM.

4 . The method of claim 1 , wherein the binding antibody or the antigen-binding fragment thereof is in a sterile composition.

5 . A method of treating a patient for multiple sclerosis comprising administering to the patient an OX2R-binding antibody or an antigen-binding fragment thereof, comprising an antigen binding site from a substantially pure or recombinant antibody, wherein the antibody specifically binds to an antigen formed by the mature amino acid sequence set forth in SEQ ID NO:20, and wherein the antibody or antigen-binding fragment thereof has agonist activity for the receptor upon binding.

6 . The method of claim 5 , wherein the OX2R-binding antibody is a monoclonal antibody.

7 . The method of claim 6 , wherein the OX2R-binding antibody or the antigen-binding fragment thereof binds the antigen with a K d of at least 30 μM.

8 . The method of claim 5 , wherein the binding antibody or the antigen-binding fragment thereof is in a sterile composition.

9 . An isolated OX2R-binding antibody or an antigen-binding fragment thereof, comprising an antigen binding site from a substantially pure or recombinant antibody, wherein the antibody specifically binds to an antigen formed by the mature amino acid sequence set forth in SEQ ID NO:20, and wherein the antibody or antigen-binding fragment thereof has agonist activity for the receptor upon binding.

10 . The OX2R-binding antibody or antigen-binding fragment thereof of claim 9 , wherein the OX2R-binding antibody is a monoclonal antibody.

11 . The OX2R-binding antibody or the antigen-binding fragment thereof of claim 10 , wherein the OX2R-binding antibody binds the antigen with a K d of at least 30 μM.

12 . The OX2R-binding antibody or the antigen-binding fragment thereof of claim 9 , wherein the binding antibody or the antigen-binding fragment thereof is in a sterile composition.

Assignments (1)
CHANGE OF NAME Recorded Mar 11, 2013
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 029959/0019 →